← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

ALK Rearranged NSCLC

MONDO:0005061 Curated 2026-07-04T00:00:00Z 8 harmonized findings
falcon · 4 citations openscientist · 69 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

ALK-rearranged NSCLC is driven by a somatic chromosomal rearrangement (most commonly an inv(2)(p21p23) fusing EML4 to the ALK kinase domain) that produces a constitutively active, ligand-independent fusion tyrosine kinase driving lung adenocarcinogenesis.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% ALK-rearranged NSCLC is defined by chromosomal rearrangements that fuse the ALK tyrosine kinase domain to partner genes, most commonly EML4, creating a ligand-independent oncoprotein that constitutively activates receptor tyrosine kinase signaling and drives lung adenocarcinogenesis
Falcon states the fusion/constitutive-kinase driver mechanism directly.
DOI:10.1177/03008916231202149
openscientist CONCORDANT 97% somatic chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2p23, most commonly fused with the echinoderm microtubule-associated protein-like 4 (EML4) gene via a small paracentric inversion inv(2)(p21p23)
OpenScientist adds the precise cytogenetic mechanism (inv(2)(p21p23)).
PMID:17625570

The EML4-ALK fusion kinase signals through multiple canonical RTK effector cascades — RAS-MAPK, PI3K-AKT-mTOR, JAK-STAT (notably STAT3), and PLCgamma — to drive proliferation and survival.

UNANIMOUS INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 95% EML4-ALK engages canonical RTK cascades that mediate proliferation, survival, motility, and adaptive resistance, notably: RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR, JAK/STAT (especially STAT3), and PLCγ-driven DAG/IP3 signaling
Falcon enumerates the same four effector pathways.
DOI:10.3390/biomedicines12020297
openscientist CONCORDANT 90% The constitutively active EML4-ALK fusion kinase drives oncogenesis through RAS-MAPK, PI3K-AKT, JAK-STAT, and PLCgamma signaling pathways, orchestrated within phase-separated cytoplasmic signaling foci
OpenScientist matches the four pathways and adds the phase-separation (biomolecular condensate) framing.

ALK+ NSCLC represents roughly 3-7% of NSCLC and is enriched in younger patients (median age ~55-60), never/light smokers, and adenocarcinoma histology.

MAJORITY INTEGRATED
epidemiologyphenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% Representing 3–7% of all NSCLC cases, this disease preferentially affects younger patients (median age 55–60 years), never-smokers (60–70%), and those with adenocarcinoma histology.
OpenScientist gives the frequency and the full demographic enrichment.
falcon PARTIAL 50% drives lung adenocarcinogenesis (approx. 2–8% of LUAD; commonly 2–3%)
Falcon gives a frequency estimate framed as a fraction of LUAD ("commonly 2–3%") that is lower than OpenScientist's 3-7% of NSCLC, and does not report the age/smoking demographic enrichment. Partial: overlapping but not fully concordant on the rate, silent on demographics.

ALK+ NSCLC has an immunosuppressive, immune-cold tumor microenvironment (low effective CD8+ activity, low tumor mutational burden), which underlies poor response to PD-1/PD-L1 checkpoint blockade.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% ALK+ NSCLC generally exhibits an immunosuppressive TIME with relatively low effective CD8+ T-cell activity and enrichment of suppressive subsets (Tregs and/or M2 macrophages), contributing to poor response to PD-1/PD-L1 blockade
Falcon links the suppressive TIME to poor checkpoint-inhibitor response.
openscientist CONCORDANT 85% fostering an immune-cold tumor microenvironment characterized by low tumor mutational burden (TMB) and CD73/adenosine-mediated immune evasion
OpenScientist agrees on the immune-cold/low-TMB phenotype and adds a specific CD73/adenosine evasion axis.

CNS involvement is frequent: brain metastases are present in a substantial fraction of patients at diagnosis and accumulate over the course, making CNS penetrance a key driver of therapy selection.

MAJORITY INTEGRATED
phenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Brain metastases present at diagnosis in 29% of patients, with a cumulative incidence exceeding 50%.
OpenScientist quantifies baseline (29%) and cumulative (>50%) CNS burden.
PMID:41043103
falcon PARTIAL 60% CNS tropism is frequent at baseline (≈20% present with brain metastases), guiding the use of CNS-penetrant TKIs
Falcon agrees CNS tropism is frequent and drives TKI choice, but reports a lower baseline figure (~20% vs OpenScientist's 29%) and no cumulative incidence — a quantitative discrepancy, not a contradiction.

EML4-ALK variant 3 is associated with inferior progression-free survival relative to variant 1 (HR ~1.53), a clinically meaningful prognostic modifier.

MAJORITY INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% EML4-ALK V3 (HR=1.53 for PFS vs V1)
OpenScientist asserts the prognostic HR for variant 3 with a PMID.
PMID:41959926
falcon PARTIAL 40% V1/V2 have incomplete TAPE domains (HSP90 dependency), whereas V3 is a short variant that co-localizes with microtubules and shows distinct signaling condensates
Falcon establishes the mechanistic/structural basis for variant-3 distinctness but does not assert the clinical prognostic association (the HR). Partial: mechanistic support without the outcome claim.

Adjuvant alectinib markedly improves disease-free survival after complete resection of stage II-IIIA ALK+ NSCLC (ALINA trial).

SINGLE INTEGRATED
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001)
OpenScientist reports the ALINA adjuvant DFS result with the pivotal quote.
PMID:38598794
falcon SILENT —
Falcon's pathophysiology-focused report does not cover the adjuvant setting or the ALINA trial at all.

Third-generation lorlatinib delivers durable long-term disease control and strong CNS protection in advanced ALK+ NSCLC (CROWN 5-year data).

MAJORITY INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% the third-generation lorlatinib, which achieved an unprecedented 5-year progression-free survival (PFS) of 60%+ in the CROWN trial with a 96% probability of preventing brain metastases
OpenScientist reports the mature CROWN 5-year efficacy and CNS-protection data.
PMID:40024442
falcon PARTIAL 45% Third-generation, CNS-penetrant ALK-TKI active against many single ALK mutations; resistance via compound mutations/bypass emerges
Falcon identifies lorlatinib as the CNS-penetrant third-generation agent but does not cite the CROWN outcome data — mechanistic/class agreement without the clinical efficacy evidence.

Narrative

Overview

Both providers frame ALK-rearranged NSCLC as a fusion-driven lung adenocarcinoma subtype enriched in younger never/light smokers, with oncogene addiction to ALK signaling, modern ALK TKI sequencing, CNS involvement, and acquired resistance as the major curated concepts.

Agreement

Both agree on the core driver biology (EML4-ALK constitutive kinase), the multi-pathway effector signaling (RAS-MAPK, PI3K-AKT, JAK-STAT, PLCgamma), the immune-cold/low-TMB microenvironment and poor checkpoint-inhibitor response, and the clinical prominence of CNS metastasis driving TKI choice.

Divergence

Falcon emphasized the existing ALK inhibitor landscape and broad diagnostic and immunotherapy context. OpenScientist added more recent clinical and mechanistic detail: variant 3 prognosis (HR 1.53), ALINA adjuvant alectinib, five-year CROWN lorlatinib data, and resistance mechanisms involving EMT, CAF-driven HGF-MET and integrin signaling, and SRC bypass signaling. The only quantitative discrepancies are minor (prevalence framing; baseline brain-metastasis fraction 20% vs 29%) — not contradictions.

Integration

Integrated into kb/disorders/ALK_Rearranged_NSCLC.yaml: overview and EML4-ALK subtype updated for ongoing CNS/resistance challenges and the adverse PFS of variant 3; the ALK TKI resistance node expanded to EMT, CAF/HGF-MET/ integrin, SRC, and bypass biology; brain-metastasis evidence refreshed with CNS-active ALK inhibitor data; ALINA support added to alectinib and CROWN five-year support to lorlatinib.

Not integrated (leads)

Investigational ALK combinations, detailed adverse-event management, and broad immunotherapy sequencing claims were retained as research leads rather than promoted to curated disease mechanisms.

Prototype for the cross-provider synthesis schema (src/dismech/schema/research_synthesis.yaml). Two independent reports were compared: falcon (pathophysiology-focused) and openscientist (comprehensive, 15-domain). A third file, ALK_Rearranged_NSCLC-deep-research-cyberian-codex.md, is a local codex re-synthesis derived from falcon rather than an independent provider run, so it is excluded from the providers list. No direct contradictions were found between the two reports; divergence is coverage/recency (OpenScientist adds variant-3 prognosis, ALINA adjuvant, and CROWN 5-year data that Falcon predates or omits) plus a minor quantitative discrepancy on prevalence and baseline brain-metastasis fraction. `best_matching_text` values are verbatim excerpts from the cited report files; literature `evidence:` snippets were intentionally left unpopulated pending fetch-reference verification of the underlying PMIDs/DOIs.